Exelixis (EXEL)
(Delayed Data from NSDQ)
$20.99 USD
-0.28 (-1.32%)
Updated May 14, 2024 04:00 PM ET
After-Market: $21.00 +0.01 (0.05%) 6:24 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
Brokerage Reports
Exelixis, Inc. [EXEL]
Reports for Purchase
Showing records 1 - 20 ( 176 total )
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Full-Year 2023 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
CONTACT-02 Trial Results Presented; 2024 Outlook; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for EXEL 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Zanzalintinib Shines in ccRCC Expansion Cohort; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Financial Results Reported; Encouraging CABINET Pivotal Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Exelixis, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department